Eli Lilly said on Thursday it would appeal against a UK agency's recommendation to not reimburse the cost of Alzheimer's drug ...

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...

Eli Lilly shares have soared in value in recent years due to the success of its GLP-1 drugs. Viking Therapeutics and ...

Zoetis was created in 2013 after splitting off from Pfizer’s animal health division. While it may not seem like a household ...

Shares of Scholar Rock Holdings jumped Wednesday after the biopharmaceutical firm reported positive results from a ...

Scholar Rock (NASDAQ:SRRK) announced Wednesday that its lead candidate, apitegromab, in combination with Eli Lilly’s ...

According to Adam Parker, founder of Trivariate Research, investors aiming for a defensive approach might want to look at ...

Verve Therapeutics remains an early-stage biotech, making the rally purely acquisition-driven, not based on fundamentals.

Eli Lilly's Zepbound is the first and only approved dual GLP-1/GIP agonist, and Lilly is also working on its own triple ...

On the sidelines of BIO2025, Julie Gilmore, head of Lilly Gateway Labs, shares her thoughts on the $1.3 billion Verve Therapeutics buy, where Lilly’s therapeutic puck is potentially going and how the ...

Scholar Rock's apitegromab helped preserve muscle mass during tirzepatide-induced weight loss, improving overall body ...

In combination with Eli Lilly’s tirzepatide, marketed as Zepbound for obesity, Scholar Rock’s monolonal antibody helped ...